Serious conditions attract serious attention. Acute myeloid leukemia (AML) is a devastating form of cancer with a poor prognosis and limited treatment options. Already, a raft of biotechs has thrown resources at the disease, but with more failure than success. Now, TORCell Therapeutics Inc., a biotech spun out of the Ontario Institute for Cancer Research (OICR) in Toronto, is taking aim at AML with a technology to boost a patient's own double-negative T cells (DNT) – a subpopulation of T lymphocytes that has potent anticancer properties, but comprises only 1 percent of a patient's peripheral blood mononuclear cells.